Avid Bioservices Inc (CDMO)

[biopharm]

Joe Munda

Joe Munda is going to be something one day. If you run a Hedge Fund and want to meet a Tremendous Analyst find Joe Munda. He passes my Test https://t.co/cFoJH9ZunM

— Marc Cohodes (@AlderLaneEggs) October 31, 2017

___

I don't know where Steve Schwartz went as LinkedIn says he was done at First Analysis Securities ...heck, maybe he had intentions to go public and tell everyone how valuable the IP assets are where Avid Bioservices receives 15% royalties etc and all manufacturing rights etc etc .....and will show up as co-CEO with Rahul at Pelican or a promotion at his ex employer ThermoFisher that has been working with Mark Bamforth


____

Cheynew, did you have a copy of the transcript where Rahul asked some good questions ? re: IP assets of Peregrine and strings were pulled to not let news get out on how valuable the IP assets are .... as Rahul found out

Avid Bioservices now has that unique business model of a CDMO with manufacturing rights to IP assets / related IO drugs



____

Rahul R. Jasuja, PhD

CEO, Pelican Therapeutics

Rahul R. Jasuja is CEO of Pelican Therapeutics, a subsidiary of Heat Biologics. He previously served as Senior Biotechnology Analyst at FBR & Co., as well as Managing Director, Biotechnology Research, at Noble Life Science Partners (NLSP). Prior to NLSP, Dr. Jasuja was Vice President of Corporate Development at Idera Pharmaceuticals, focused on developing Toll-like receptor based immune-modulators. He has also held progressively senior positions within the biotechnology capital markets at Techvest LLC, Rodman & Renshaw and MDB Capital Group.

Dr. Jasuja brings more than 20 years of experience in the biotechnology field, including corporate/business development, technology due-diligence, equity research and academic research. Rahul received his Ph.D. in Immunology from Tufts University School of Medicine in which he explored aspects T-cell activation and the subsequent regulation of adhesion receptors in the immune response. He conducted doctoral and post-doctoral research at Harvard Medical School, in the Department of Hematology & Oncology at Beth Israel Deaconess Medical Center.

Dr. Jasuja obtained his B.Sc. in Microbiology & Biochemistry from the University of Bombay and an M.S. in Microbiology from the University of Montana, Missoula, where he studied the role of bacterial cell wall immune modulators on arachidonic acid metabolism and inflammatory pathways in macrophages.